The present invention discloses a method for the prevention of atherosclerosis, its genesis, progression and restenosis in human patients undergoing treatments for arterial lesions such as PTA or atherectomy, and which may be accompanied by stent implantation. Further, the treatment method disclosed has applicability in all stages of atherosclerosis in which monocytes play a role. The compound utilized in the present method as the active agent is a 2-halo-2′-deoxyadenosine such as 2-chloro-deoxyadenosine (2-CdA). The treatment method of the present invention includes the administration of 14 doses of 2-CdA in the amount of 0.12 mg/kg. One dose is given intravenously before the coronary intervention, another is given intravenously after the intervention and the remaining twelve doses are given subcutaneously at weekly intervals over a subsequent three month period.
|
1. A method for preventing a restenosis at a location of an inflammation in the vasculature of a patient which comprises the steps of:
apportioning a medicament into a plurality of therapeutically effective doses, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:
##STR00002##
wherein Y is a halogen, each said dose of said medicament being efficacious for responding to said inflammation by reducing monocytes in the blood to below a preselected level; and
administering at least one of said doses to a human in accordance with a predetermined regimen.
0. 16. A method for preventing a restenosis at a location of an inflammation in the vasculature of a patient which comprises the steps of:
apportioning a medicament into a plurality of therapeutically effective doses, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:
##STR00004##
wherein Y is a halogen, each said dose of said medicament being efficacious for responding to said inflammation by reducing monocytes in the blood to below a preselected level; and
administering at least one of said doses to a human topically with a carrier in accordance with a predetermined regimen.
11. A method for reducing the production of monocytes in a patient to prevent a restenosis wherein said method comprises the steps of:
preparing fourteen individual portions of a medicament, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:
##STR00003##
wherein Y is a halogen;
administering a first said portion of said medicament to said human prior to a catheter procedure;
providing a second said portion of said medicament to said human subsequent said catheter procedure; and
dispensing one of said remaining twelve portions of said medicament at consecutive weekly intervals over a twelve week period immediately following said administering of said second said portion of said medicament.
4. The method as recited in
5. The method as recited in
6. The method as recited in
7. The method as recited in
preparing fourteen individual portions of said medicament;
administering a first said portion of said medicament to said human prior to a catheter procedure;
administering a second said portion of said medicament to said human subsequent said catheter procedure; and
administering one of said remaining twelve portions of said medicament at consecutive weekly intervals over a twelve week period immediately following said administering of said second said portion of said medicament.
8. The method as recited in
9. The method as recited in
10. The method as recited in
12. The method as recited in
13. The method as recited in
14. The method as recited in
15. The method as recited in
0. 17. The method as recited in
0. 18. The method as recited in
|
|||||||||||||||||||||||||
The present invention pertains generally to the prevention of atherosclerosis, its genesis, progression and restenosis following vascular repair. More specifically, the present invention pertains to the administration of a therapeutically effective dose of a substituted adenine derivative to prevent atherosclerosis, its genesis, progression and restenosis following vascular repair. The present invention is particularly, but not exclusively, useful for preventing a restenosis in human patients who have undergone a catheter based procedure, which may include a subsequent stent implantation, to dilate an arterial blockage in the patient's vasculature.
Arteriosclerosis, the group of diseases characterized by plaque deposition and gradual blockage of blood flow in arterial vessels, may result in ischemia of the heart, brain or extremities, resulting in infarction and sometimes death. Over 2,000,000 vascular interventions are performed each year worldwide with over 800,000 of these being performed in the United States. Since about 1977, blocked arteries have been treated using a balloon catheter. This procedure, known as percutaneous transluminal angioplasty (PTA), involves the insertion of a catheter into the lumen of a blocked artery and the inflation of an attached balloon to open the artery (both coronary and non-coronary vessels). Another catheter procedure, commonly known as atherectomy, opens a blocked artery by grinding or cutting plaque deposits and suctioning the deposits from the artery. More recently, metal structures called stents have been placed in the affected artery to keep the previously blocked artery open after PTA or atherectomy treatment. Presently, over 70% of persons currently treated for arterial lesions have implanted stents.
It is fortunate that over 90% of coronary interventions are successful in opening the blocked artery. However, the later renarrowing of the opened artery, (i.e. restenosis) remains a significant problem. Unfortunately, within six months after a first PTA or atherectomy treatment, restenosis occurs in about 30% to 50% of patients. When restenosis occurs, either another PTA or atherectomy treatment is performed, and another stent is implanted, or bypass surgery is performed. After a second catheter procedure, restenosis occurs in about 60% of patients, who then must undergo yet another catheter procedure or submit to bypass surgery.
Though many details of restenosis remain unclear, the general consensus is that angioplasty and stenting, either individually or collectively, cause a stretch and tear injury to the arterial wall which results in an inflammation that leads to the activation of multiple cell lines. In particular, there is concern for the monocyte/macrophage line. Specifically, it is known that monocytes will migrate to the area of an arterial injury. There, they are differentiate into tissue macrophages and secrete cytokines and growth factors which cause the migration and proliferation of smooth muscle cells into the area. This results in excessive tissue growth or restenosis.
Not surprisingly, efforts have been taken to prevent restenosis. For example, medications such as calcium channel blockers, corticosteroids, antiplatelet agents, fish oils, lovastatin and anticoagulants have been tried in attempts to prevent restenosis. Heretofore, however, these efforts have been generally unsuccessful. Radiation therapy has been shown to reduce restenosis, but radiation therapy is generally impractical because it is time consuming, requires specialized equipment, specialized personnel, and is often difficult to arrange. Some immunosuppressants, on the other hand, show promise.
It is known that the immunosuppressant medication 2-chloro-deoxyadenosine (2-CdA) is selectively toxic to monocytes, and is effective in lowering monocyte levels in humans. Presently, this medication (2-CdA) has been FDA approved for use in the treatment of hairy cell leukemia, and also has activity in cutaneous T-cell lymphoma, myeloid leukemias, chronic lymphocytic leukemia, Langerhans cell histiocytosis and non-Hodgkin's lymphoma. Additionally, FDA approval has been sought for treatment of multiple sclerosis. As a new and useful application, the present invention discloses a method of preventing restenosis by administering a therapeutically effective dose of 2-CdA.
In light of the above, it is an object of the present invention to provide a method for preventing a restenosis in the vasculature of a patient which promotes a systemic suppression to the inflammation response that provokes a restenosis. Another object of the present invention is to provide a method for preventing a restenosis in the vasculature of a patient which uses a medication that can be administered orally, subcutaneously, intravenously, intramuscularly, or topically. Yet another object of the present invention is to provide a method for preventing restenosis in the vasculature of a patient which minimizes adverse side effects and, thus, is minimally intrusive into a patient's life style and quality of life. It is still another object of the present invention to provide a method for preventing a restenosis in the vasculature of a patient which uses a medication that is relatively easy to administer, is effective for its intended purpose, and is comparatively cost effective.
The present invention discloses a method of treatment for progression of atherosclerosis and the prevention of restenosis in human patients who have submitted to catheter procedures, such as PTA or atherectomy, and who may subsequently require stent implantation in the area of an arterial lesion. In accordance with the present invention, the compound which is utilized as the active agent in the treatment is a 2-halo-2′-deoxyadenosine, which has a structure that corresponds to that of formula:
##STR00001##
Wherein Y is a halogen, either fluoro, chloro or bromo, but preferably chloro. When Y is chloro, the compound is 2-chloro-deoxyadenosine (2-CdA).
There is general agreement that restenosis is caused by the body's response to the inflammation that is associated with PTA and stent implantation. In this response, monocytes are generated and migrate in the blood to the damaged area of the artery. Once there, the monocytes differentiate into macrophages which, in turn, secrete cytokines and growth factors resulting in the migration and proliferation of the smooth muscle cells that contribute to a restenosis. Administration of 2-CdA, however, is known to kill monocytes and hence lower the monocyte level in humans. In accordance with the present invention, this result is used for the specific purpose of suppressing or preventing a restenosis.
One embodiment of the method of this invention includes the administration of 14 doses of 2-CdA in equal dosages of 0.12 mg/kg of body weight. Prior to the procedure used to obviate the arterial lesion, such as (PTA), the first dose is given. The remaining 12 equivalent doses are given thereafter at weekly intervals.
A particular advantage of the present invention is the convenient dosing regimen. Further, as intended for the present invention, dosages can be given either orally in a pill form, intravenously, subcutaneously or intramuscularly with injections, or topically, such as with the use of a carrier. In this aspect, a stent may be used as a carrier. Another advantage of the present invention is that 2-CdA has been FDA approved for the treatment of hairy cell leukemia, thus confirming a substantial safety profile for its use in human patients.
As mentioned above, there is general agreement that catheter procedures such as angioplasty, atherectomy and/or stenting causes a stretch and tear injury to the arterial wall which causes an inflammation. This inflammation leads to the activation of multiple cell lines, and in particular, the monocyte/macrophage line. Monocytes, which are immune cells derived from the bone marrow, migrate to the area of arterial injury, where they differentiate into tissue macrophages and secrete cytokines and growth factors. These cytokines and growth factors then result in restenosis by causing the above normal migration and proliferation of smooth muscle cells into the area. Also, once stimulated, the macrophages secrete a variety of mitogens which stimulate the transformation of smooth muscle cells from their normal contractile state to a secretory state. Further, the macrophages are scavenger cells that can absorb lipids and attack neighboring cells. The net result is an exuberant growth of tissue which encroaches the vessel lumen resulting in restenosis.
In addition to initiating restenosis, monocytes have been implicated in every stage of atherosclerosis from the earliest fatty streaks found in children to the advanced fibromuscular lesions characterized by lipid-laden macrophages, smooth muscle cells, cholesterol crystals, and a fibrous cap. Macrophages are also believed to secrete enzymes called matrix metalloproteinases which lead to thinning and eventual rupture of the fibrous cap causing thrombosis of the coronary artery. Hence, one skilled in the art would recognize that the treatment method disclosed by the present invention may be applicable to every stage of atherosclerosis, and not merely to the prevention of restenosis.
The medication 2-chloro-deoxyadenosine (LEUSTATIN®, Cladribine, or 2-CdA) is a potent immunosuppressant selectively toxic to monocytes and lymphocytes, and is effective in lowering the monocyte levels in humans. Although the exact mechanism by which 2-CdA causes cell death in monocytes is unknown, a mechanism has been established whereby 2-CdA causes cell death in lymphocytes. This mechanism proceeds as follows: 2-CdA in the bloodstream enters the lymphocyte cell, passively crossing the cell membrane. Once inside the lymphocyte cell, 2-CdA is phosphorylated by the lymphocyte enzyme deoxycytidine kinase. Once phosphorylated, the 2-CdA can accumulate in the lymphocyte cell because it is resistant to deamination by adenosine deaminase. Phosphorylated 2-CdA is toxic to lymphocytes by causing impaired DNA synthesis and repair resulting in impaired RNA and protein synthesis and, ultimately, apoptosis or cell death.
This medication, 2-CdA, has been FDA approved for use in the treatment of hairy cell leukemia, and has activity in cutaneous T-cell lymphoma, myeloid leukemias, chronic lymphocytic leukemia, langerhans cell histiocytosis and non-Hodgkin's lymphoma. Further, FDA approval has been sought for the use of 2-CdA in the treatment of multiple sclerosis. Use of 2-CdA in the above listed treatments has generated a favorable safety profile for use in humans.
Hence, the present invention discloses a method of preventing atherosclerosis, its genesis, progression and restenosis by administering a therapeutically effective dose of 2-CdA to temporarily lower the monocyte level in the blood and specifically near the area of arterial inflammation. Lowering the monocyte level for a three month period following coronary intervention is preferred.
One embodiment of the method of the present invention includes the administration of 14 doses of 2-CdA in a pharmacologically acceptable carrier or a pharmacologically acceptable acid addition salt of 2-CdA to the patient. As summarized in the following table, an exemplary therapeutic dosage of 0.12 mg/kg of body weight is given prior to the catheter procedure used to obviate the arterial lesion. An equivalent second dose is given one day subsequent to the procedure, and the remaining 12 equivalent doses are given thereafter at weekly intervals.
Dose (mg/kg of
Method of
body weight)
Administration
Time of Administration
0.12
Intravenously
Prior to Catheter Procedure
0.12
Intravenously
Day After Catheter Procedure
0.12
Subcutaneously
One week after Catheter Procedure
0.12
Subcutaneously
Two weeks after Catheter Procedure
0.12
Subcutaneously
Three weeks after Catheter Procedure
0.12
Subcutaneously
Four weeks after Catheter Procedure
0.12
Subcutaneously
Five weeks after Catheter Procedure
0.12
Subcutaneously
Six weeks after Catheter Procedure
0.12
Subcutaneously
Seven weeks after Catheter Procedure
0.12
Subcutaneously
Eight weeks after Catheter Procedure
0.12
Subcutaneously
Nine weeks after Catheter Procedure
0.12
Subcutaneously
Ten weeks after Catheter Procedure
0.12
Subcutaneously
Eleven weeks after Catheter Procedure
0.12
Subcutaneously
Twelve weeks after Catheter Procedure
Although the 2-CdA could be administered in several ways including orally, topically, subcutaneously, intravenously or intramuscularly, it is practical to administer the first two dosages intravenously since the recipient is generally a hospital patient when the dosage is required, while the remaining dosages are given subcutaneously by medical personnel at outpatient clinics or in the home.
While the particular method as herein disclosed in detail is fully capable of obtaining the objects and providing the advantages herein before stated, it is to be understood that it is merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended to the details of construction or design here in shown other than as described in the appended claims.
Schatz, Richard A., Saven, Alan
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 5106837, | Feb 03 1986 | SCRIPPS RESEARCH INSTITUTE, THE, A CORP OF CA | Adenosine derivatives with therapeutic activity |
| 5424296, | Apr 15 1993 | SCRIPPS RESEARCH INSTITUTE, THE | 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma |
| 5510336, | Sep 06 1994 | 2-halo-2'-deoxyadenosine treatment for histiocytosis |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Feb 18 2004 | Conor Medsystems, Inc. | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Oct 30 2008 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Nov 26 2008 | STOL: Pat Hldr no Longer Claims Small Ent Stat |
| Dec 01 2008 | R2552: Refund - Payment of Maintenance Fee, 8th Yr, Small Entity. |
| Oct 01 2012 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Date | Maintenance Schedule |
| Aug 28 2010 | 4 years fee payment window open |
| Feb 28 2011 | 6 months grace period start (w surcharge) |
| Aug 28 2011 | patent expiry (for year 4) |
| Aug 28 2013 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Aug 28 2014 | 8 years fee payment window open |
| Feb 28 2015 | 6 months grace period start (w surcharge) |
| Aug 28 2015 | patent expiry (for year 8) |
| Aug 28 2017 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Aug 28 2018 | 12 years fee payment window open |
| Feb 28 2019 | 6 months grace period start (w surcharge) |
| Aug 28 2019 | patent expiry (for year 12) |
| Aug 28 2021 | 2 years to revive unintentionally abandoned end. (for year 12) |